Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

priority access

- PMLiVE

AstraZeneca launches Nexium YouTube channel

New AZPurpleZone channel aimed at US patients with acid reflux disease offers symptom-relief advice and product savings

- PMLiVE

Comment: AstraZeneca’s branded approach to YouTube

Company takes the path less travelled for pharma social media initiatives

- PMLiVE

Simon Lowth steps down as AZ’s CFO

Joins natural gas firm BG Group in same role

- PMLiVE

Merck maintains lead in BACE inhibitors for Alzheimer’s

Positive results in phase Ib study in patients with Alzheimer’s disease

- PMLiVE

J&J files ‘breakthrough’ drug ibrutinib in US

FDA to assess drug in lymphoma and leukaemia

Novartis sponsors rare disease patient community

Backs site for patients affected by pancreatic neuroendocrine tumours (PNET)

AZ target Omthera files blood fat drug in US

FDA submission for Epanova in severe hypertriglyceridemia

- PMLiVE

Novartis enters developing nations vaccines partnership

Will work with Biological E to deliver vaccines for typhoid and paratyphoid A fevers

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis study

Phase III results show the antibody is more effective than Amgen/Pfizer's blockbuster

- PMLiVE

Interview: David Haslam, NICE

The new chair of the UK’s NICE discusses navigating the stormy waters of health service reforms, collaborating with pharma and the introduction of VBP

Novartis day

Lucentis cleared in Europe for pathological myopia

Makes Novartis' drug the first anti-VEGF approved in this setting

- PMLiVE

Setback for Merck & Co as FDA knocks back insomnia drug

US regulator asks for company to file for approval of a lower starting dose of suvorexant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links